[SL2] 特別講演2

[SL2-1] OMNITM Triple-platform technology - Removing the barriers in CRISPR-based gene editing therapy

^○David Baram¹, Liat Rockah¹, Milit Marom¹, Shira Warszawski¹, Nir Hecht¹, Nir Shpak¹, Rivkah Rogawski¹, Shir Weber¹, Veronica Moskovicz¹, Bar Dagan¹, Tami Khazma¹, Maya Noff¹, Nir Shahar¹, Dotan Omer¹, Roy Sirkis¹, David C. Dale², Asael Herman¹, Rafi Emmanuel¹, Lior Izhar¹ (1.EmendoBio, Inc., New York, USA, 2.Department of Medicine, University of Washington, Seattle, WA, USA)

Dr. David Baram co-founded EmendoBio and has served as its President & CEO since that time. Under his leadership, David has taken EmendoBio from the pre-seed stage through multiple financing rounds and a successful acquisition in 2020. Prior to EmendoBio, David co-founded multiple biotech companies and a seed-stage incubator in which he was responsible for technological innovation, entrepreneurship and financing. David lead the negotiation and execution of a broad range of deals including mergers & acquisitions, out-licensing, and in-licensing, fundraising over $500 million in private and public rounds, and serving as a member of the board of directors for several biotech companies. David is an inventor of over thirty patents. He completed his Ph.D. studies at the Weizmann Institute of Science under Nobel Laureate Dr. Ada Yonath.